What Next: TBD | Tech, power, and the future
Technology
The diabetes medication Ozempic has exploded in popularity, particularly amongst those in Hollywood looking to lose a few extra pounds. But a silver bullet for weight loss leads to a number of questions: Is “buying weight loss” via injection somehow worse than diet and exercise? Are so many people buying and using this drug that people who need it for its intended purpose are missing out? What happened to body positivity?
Guest: Matthew Schneier, feature writer for New York Magazine.
Host: Lizzie O’Leary
If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Did A.I. Write This Headline?
Will Google Get Broken Up?
Does Meta Even Care When Its Users Get Hacked?
An Antivax Dog Whistle Goes Viral
Tesla’s No Good, Very Bad Year
Why the Feds Want to Kill Noncompetes
How War in Taiwan Could Short-Circuit U.S. Tech
Will Southwest Be Held Accountable?
One Year - 1942: The Most Hated Man in America
Are You Ready For Lab-Grown Meat?
SBF's Worst Week Yet
San Francisco’s Self-Driving Mess
Let’s Talk, Chatbots
Big Tech’s Boogeymen In Washington
Twitter's Vulnerabilities, Exposed
The Trap of Buy Now, Pay Later
The End of the Tech Boom
The Case Against Climate Reparations
Is This The Cryptocalypse?
Senator Chris Murphy on Elon's Acquisition of Twitter
Create your
podcast in
minutes
It is Free
Slow Burn
Slate Debates
What Next | Daily News and Analysis
Decoder Ring
Amicus With Dahlia Lithwick | Law, justice, and the courts